Unsafe, Not Effective, $3.2 Million Per Dose: Why Is This Drug Still Available? Robert M. Kaplan February 11, 2026

https://www.healthaffairs.org/content/forefront/unsafe-not-effective-3-2-million-per-dose-why-drug-still-available?utm_campaign=forefront&utm_medium=email&_hsenc=p2ANqtz-8ewAGzaN5lB67BjjLmKVbblzizyoB30RKxSM43aMIwFvtZBCy0vBq15syuTeBV2bo-Bq4hE6G_UG8UJ9E5XbJS3Cc7ig&_hsmi=403582794&utm_source=hasu On June 20, 2024, the Food and Drug Administration granted accelerated approval for Elevidys (delandistrogene moxeparvovec), a gene-transfer therapy for boys four years and older with Duchenne muscular dystrophy (DMD). The price for a single infusion was listed at $3.2 million, making Elevidys one of the most expensive medicines in the world.